<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Clinical trials on FinanClub</title>
    <link>https://finan.club/tags/clinical-trials/</link>
    <description>Recent content in Clinical trials on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 29 Jan 2024 09:07:52 +0000</lastBuildDate><atom:link href="https://finan.club/tags/clinical-trials/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>MRK</title>
      <link>https://finan.club/us/mrk/</link>
      <pubDate>Mon, 29 Jan 2024 09:07:52 +0000</pubDate>
      
      <guid>https://finan.club/us/mrk/</guid>
      <description>score:44
Chances: Merck &amp;amp; Co., Inc. is showing positive growth trends in the pharmaceutical and animal health segments as evidenced by the recent announcements of improved DFS and reduced risk of death for their products. The company&amp;rsquo;s collaboration with LAVA Therapeutics NV for clinical trials with Keytruda shows potential for further expansion and success in the market.</description>
    </item>
    
    <item>
      <title>TGTX</title>
      <link>https://finan.club/us/tgtx/</link>
      <pubDate>Wed, 10 Jan 2024 09:03:07 +0000</pubDate>
      
      <guid>https://finan.club/us/tgtx/</guid>
      <description>score:343
Chances: TG Therapeutics, Inc. has entered into an agreement to acquire a worldwide license to Precision BioSciences, Inc.&amp;rsquo;s Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy program for autoimmune diseases. The average of price targets set by Wall Street analysts indicates a potential upside of 127.</description>
    </item>
    
    <item>
      <title>ARWR</title>
      <link>https://finan.club/us/arwr/</link>
      <pubDate>Thu, 04 Jan 2024 09:10:03 +0000</pubDate>
      
      <guid>https://finan.club/us/arwr/</guid>
      <description>score:114
Chances: The company has successfully priced an underwritten registered offering, indicating strong investor interest and potential for significant capital influx. The filing of an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB demonstrates progress in the companyâ€™s pipeline development.</description>
    </item>
    
  </channel>
</rss>
